Immune and Neuroimmune Alterations in Mood Disorders and Schizophrenia

International Review of Neurobiology

Volumn 101, Issue , 2011, Pages 169-201

  Drexhage, Roosmarijn C ^a   Weigelt, Karin ^a   van Beveren, Nico ^a   Cohen, Dan ^b,c   Versnel, Marjan A ^a   Nolen, Willem A ^b   Drexhage, Hemmo A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Department for Diagnostics and Casemanagement of Dementia (DOC team)   (Netherlands)

Author keywords

Anti inflammatory; Bipolar disorder; Immune system; Proinflammatory; Schizophrenia

Indexed keywords

CHEMOKINE; CYTOKINE; OMEGA 3 FATTY ACID; TRYPTOPHAN;

AMINO ACID METABOLISM; BIPOLAR DISORDER; BOOK; BRAIN METABOLISM; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL FUNCTION; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; IMMUNE DYSREGULATION; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; INFECTION; INFLAMMATORY DISEASE; LYMPHOCYTE COUNT; MACROPHAGE; MICROGLIA; MONOCYTE; NEUROIMMUNOLOGY; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; STRESS; T LYMPHOCYTE SUBPOPULATION;

EID: 80055068784     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-387718-5.00007-9     Document Type: Chapter

References (120)

1. Abe H., Hidaka N., Kawagoe C., Odagiri K., Watanabe Y., Ikeda T., Ishizuka Y., Hashiguchi H., Takeda R., Nishimori T., Ishida Y. Prenatal psychological stress causes higher emotionality, depression-like behavior, and elevated activity in the hypothalamo-pituitary-adrenal axis. Neurosci. Res. 2007, 59(2):145-151.
2. Amsterdam J.D., Maislin G., Hooper M.B. Suppression of herpes simplex virus infections with oral lithium carbonate-a possible antiviral activity. Pharmacotherapy 1996, 16(6):1070-1075.
3. Arnold S.E., et al. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch. Gen. Psychiatry 1998, 55(3):225-232.
4. Austin M.P., Leader L.R., Reilly N. Prenatal stress, the hypothalamic-pituitary-adrenal axis, and fetal and infant neurobehaviour. Early Hum. Dev. 2005, 81(11):917-926.
5. Bessis A., Bechade C., Bernard D., Roumier A. Microglial control of neuronal death and synaptic properties. Glia 2007, 55(3):233-238.
6. Bosker F.J., et al. Poor replication of candidate genes for major depressive disorder using genome-wide association data. Mol. Psychiatry 2011, 16:516-532.
7. Breunis M.N., Kupka R.W., Nolen W.A., et al. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol. Psychiatry 2003, 53(2):157-165.
8. Brietzke E., Stertz L., Fernandes B., et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J. Affect. Disord. 2009, 116(3):214-217.
9. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am. J. Psychiatry 2010, 167(3):261-280.
10. Carruthers V.B., Suzuki Y. Effects of Toxoplasma gondii infection on the brain. Schizophr. Bull. 2007, 33(3):745-751.
11. Cazzullo C.L., Saresella M., Roda K., et al. Increased levels of CD8+ and CD4+ 45RA+lymphocytes in schizophrenic patients. Schizophr. Res. 1998, 31(1):49-55.
12. Chen S.K., et al. Hematopoietic origin of pathological grooming in Hoxb8 mutant mice. Cell 2010, 141(5):775-785.
13. Chesnokova V., Melmed S. Minireview: neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules. Endocrinology 2002, 143(5):1571-1574.
14. Chiu C.C., Huang S.Y., Chen C.C., Su K.P. Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder. J. Clin. Psychiatry 2005, 66(12):1613-1614.
15. Coelho F.M., Reis H.J., Nicolato R., et al. Increased serum levels of inflammatory markers in chronic institutionalized patients with schizophrenia. Neuroimmunomodulation 2008, 15(2):140-144.
16. Cohen D., Dekker J.J., Peen J., Gispen-de Wied C.C. Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment. Eur. Neuropsychopharmacol. 2006, 16(3):187-194.
17. Conejero-Goldberg C., Torrey E.F., Yolken R.H. Herpesviruses and Toxoplasma gondii in orbital frontal cortex of psychiatric patients. Schizophr. Res. 2003, 60(1):65-69.
18. Costello E.J., Worthman C., Erkanli A., Angold A. Prediction from low birth weight to female adolescent depression: a test of competing hypotheses. Arch. Gen. Psychiatry 2007, 64(3):338-344.
19. Craddock R.M., Lockstone H.E., Rider D.A., et al. Altered T-cell function in schizophrenia: a cellular model to investigate molecular disease mechanisms. PLoS One 2007, 2(1):e692.
20. Crespo-Facorro B., Carrasco-Marin E., Perez-Iglesias R., et al. Interleukin-12 plasma levels in drug-naive patients with a first episode of psychosis: effects of antipsychotic drugs. Psychiatry Res. 2008, 158(2):206-216.
21. Dahlman I., Kaaman M., Olsson T., et al. A unique role of monocyte chemoattractant protein 1 among chemokines in adipose tissue of obese subjects. J. Clin. Endocrinol. Metab. 2005, 90(10):5834-5840.
22. Doorduin J., et al. [(11)C]-DPA-713 and [(18)F]-DPA-714 as New PET tracers for TSPO: a comparison with [(11)C]-(R)-PK11195 in a rat model of herpes encephalitis. Mol. Imaging Biol. 2009, 11(6):386-398.
23. Drexhage R.C., Padmos R.C., de Wit H., et al. Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: association with the metabolic syndrome in patients?. Schizophr. Res. 2008, 102(1-3):352-355.
24. Drexhage R.C., van der Heul-Nieuwenhuijsen L., Padmos R.C., van Beveren N., Cohen D., Versnel M.A., Nolen W.A., Drexhage H.A. Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int. J. Neuropsychopharmacol. 2010, 13(10):1369-1381.
25. Drexhage R.C., Hoogenboezem T.A., Cohen D., Versnel M.A., Nolen W.A., van Beveren N.J., Drexhage H.A. An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces. Int. J. Neuropsychopharmacol. 2011, 24:1-10.
26. Drexhage R.C., Hoogenboezem T.H., Versnel M.A., Berghout A., Nolen W.A., Drexhage H.A. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav. Immun. 2011, 25:1206-1213.
27. Ebrinc S., Top C., Oncul O., Basoglu C., Cavuslu S., Cetin M. Serum interleukin 1 alpha and interleukin 2 levels in patients with schizophrenia. J. Int. Med. Res. 2002, 30(3):314-317.
28. Erbagci A.B., Herken H., Koyluoglu O., Yilmaz N., Tarakcioglu M. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm. 2001, 10(3):109-115.
29. Falke E., Han L.Y., Arnold S.E. Absence of neurodegeneration in the thalamus and caudate of elderly patients with schizophrenia. Psychiatry Res. 2000, 93(2):103-110.
30. Fallon B.A., Nields J.A. Lyme disease: a neuropsychiatric illness. Am. J. Psychiatry 1994, 151(11):1571-1583.
31. Frangou S., Lewis M., McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br. J. Psychiatry 2006, 188:46-50.
32. Frommberger U.H., Bauer J., Haselbauer P., Fraulin A., Riemann D., Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur. Arch. Psychiatry Clin. Neurosci. 1997, 247(4):228-233.
33. Grundy S.M., Brewer H.B., Cleeman J.I., et al. Definition of metabolic syndrome: report of the national heart, lung, and blood institute/American heart association conference on scientific issues related to definition. Circulation 2004, 109(3):433-438.
34. Haack M., Hinze-Selch D., Fenzel T., et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J. Psychiatr. Res. 1999, 33(5):407-418.
35. Hashimoto M., Watanabe T., Fujioka T., Tan N., Yamashita H., Nakamura S. Modulating effects of prenatal stress on hyperthermia induced in adult rat offspring by restraint or LPS-induced stress. Physiol. Behav. 2001, 73(1-2):125-132.
36. Henneberg A., Riedl B., Dumke H.O., Kornhuber H.H. T-lymphocyte subpopulations in schizophrenic patients. Eur. Arch. Psychiatry Neurol. Sci. 1990, 239(5):283-284.
37. Hillegers M.H., Burger H., Wals M., Reichart C.G., Verhulst F.C., Nolen W.A., Ormel J. Impact of stressful life events, familial loading and their interaction on the onset of mood disorders: study in a high-risk cohort of adolescent offspring of parents with bipolar disorder. Br. J. Psychiatry 2004, 185:97-101.
38. Hinze-Selch D. Infection, treatment and immune response in patients with bipolar disorder versus patients with major depression, schizophrenia or healthy controls. Bipolar Disord. 2002, 4(Suppl. 1):81-83.
39. Hori H., Yoshimura R., Yamada Y., et al. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int. Clin. Psychopharmacol. 2007, 22(1):21-27.
40. Jia P., et al. Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. Schizophr. Res. 2010, 122(1-3):38-42.
41. Jones-Brando L., Torrey E.F., Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr. Res. 2003, 62(3):237-244.
42. Kamei N., Tobe K., Suzuki R., et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J. Biol. Chem. 2006, 281(36):26602-26614.
43. Kaminska T., Wysocka A., Marmurowska-Michalowska H., Dubas-Slemp H., Kandefer-Szerszen M. Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch. Immunol. Ther. Exp. (Warsz.) 2001, 49(6):439-445.
44. Kauer-Sant'Anna M., Kapczinski F., Andreazza A.C., et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. Late-stage bipolar disorder. Int. J. Neuropsychopharmacol. 2009, 12(4):447-458.
45. Kim Y.K., Kim L., Lee M.S. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr. Res. 2000, 44(3):165-175.
46. Kim Y.K., Suh I.B., Kim H., et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol. Psychiatry 2002, 7(10):1107-1114.
47. Kim Y.K., Myint A.M., Lee B.H., et al. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res. 2004, 129(3):267-272.
48. Kim Y.K., Myint A.M., Lee B.H., et al. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28(7):1129-1134.
49. Kim Y.K., Myint A.M., Verkerk R., Scharpe S., Steinbusch H., Leonard B. Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology 2009, 59(2):123-129.
50. Knijff E.M., et al. A relative resistance of T cells to dexamethasone in bipolar disorder. Bipolar Disord. 2006, 8(6):740-750.
51. Kronfol Z., House J.D. Immune function in mania. Biol. Psychiatry 1988, 24(3):341-343.
52. Kronig H., Riedel M., Schwarz M.J., et al. ICAM G241A polymorphism and soluble ICAM-1 serum levels: evidence for an active immune process in schizophrenia. Neuroimmunomodulation 2005, 12(1):54-59.
53. Kudoh A., Sakai T., Ishihara H., Matsuki A. Plasma cytokine response to surgical stress in schizophrenic patients. Clin. Exp. Immunol. 2001, 125(1):89-93.
54. Kudoh A., Takase H., Takahira Y., Katagai H., Takazawa T. Postoperative confusion in schizophrenic patients is affected by interleukin-6. J. Clin. Anesth. 2003, 15(6):455-462.
55. Laviola G., Rea M., Morley-Fletcher S., Di Carlo S., Bacosi A., De Simone R., Bertini M., Pacifici R. Beneficial effects of enriched environment on adolescent rats from stressed pregnancies. Eur. J. Neurosci. 2004, 20(6):1655-1664.
56. Leaf A., Weber P.C. A new era for science in nutrition. Am. J. Clin. Nutr. 1987, 45(Suppl. 5):1048-1053.
57. Leonard B.E. HPA and immune axes in stress: involvement of the serotonergic system. Neuroimmunomodulation 2006, 13(5-6):268-276.
58. Lin A., Kenis G., Bignotti S., et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res. 1998, 32(1):9-15.
59. Liu X., et al. Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy. Curr. Cancer Drug Targets 2009, 9(8):938-952.
60. Maccari S., Morley-Fletcher S. Effects of prenatal restraint stress on the hypothalamus-pituitary-adrenal axis and related behavioural and neurobiological alterations. Psychoneuroendocrinology 2007, 32(Suppl. 1):S10-S15.
61. Maes M., Meltzer H.Y., Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr. Scand. 1994, 89(5):346-351.
62. Maes M., Bocchio Chiavetto L., Bignotti S., et al. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur. Neuropsychopharmacol. 2000, 10(2):119-124.
63. Maino K., Gruber R., Riedel M., Seitz N., Schwarz M., Muller N. T- and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment. Psychiatry Res. 2007, 152(2-3):173-180.
64. McGowan P.O., et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat. Neurosci. 2009, 12(3):342-348.
65. Merlot E., Couret D., Otten W. Prenatal stress, fetal imprinting and immunity. Brain Behav. Immun. 2008, 22(1):42-51.
66. Miura H., et al. A link between stress and depression: shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression. Stress 2008, 11(3):198-209.
67. Monteleone P., Fabrazzo M., Tortorella A., Maj M. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res. 1997, 71(1):11-17.
68. Muller N., Empl M., Riedel M., Schwarz M., Ackenheil M. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 1997, 247(6):308-313.
69. Muller N., Schlesinger B.C., Hadjamu M., et al. Increased frequency of CD8 positive gamma/delta T-lymphocytes (CD8+ gamma/delta+) in unmedicated schizophrenic patients: relation to impairment of the blood-brain barrier and HLA-DPA 02011. Schizophr. Res. 1998, 32(1):69-71.
70. Naudin J., Capo C., Giusano B., Mege J.L., Azorin J.M. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?. Schizophr. Res. 1997, 26(2-3):227-233.
71. Nikkila H.V., Muller K., Ahokas A., Miettinen K., Rimon R., Andersson L.C. Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes. Am. J. Psychiatry 1999, 156(11):1725-1729.
72. O'Brien S.M., Scully P., Scott L.V., Dinan T.G. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J. Affect. Disord. 2006, 90(2-3):263-267.
73. O'Brien S.M., Scully P., Dinan T.G. Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatry Res. 2008, 160(3):256-262.
74. Ortiz-Dominguez A., Hernandez M.E., Berlanga C., et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 2007, 9(6):596-602.
75. Osher Y., Bersudsky Y., Belmaker R.H. Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J. Clin. Psychiatry 2005, 66(6):726-729.
76. Oxenkrug G.F. Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophan-kynurenine metabolism. Ann. N. Y. Acad. Sci. 2010, 1199:1-14.
77. Padgett D.A., Glaser R. How stress influences the immune response. Trends Immunol. 2003, 24(8):444-448.
78. Padmos R.C., Hillegers M.H., Knijff E.M., et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch. Gen. Psychiatry 2008, 65(4):395-407.
79. Padmos R.C., Schloot N.C., Beyan H., et al. Distinct monocyte gene-expression profiles in autoimmune diabetes. Diabetes 2008, 57(10):2768-2773.
80. Padmos R.C., et al. Genetic and environmental influences on pro-inflammatory monocytes in bipolar disorder: a twin study. Arch. Gen. Psychiatry 2009, 66(9):957-965.
81. Parker G., Gibson N.A., Brotchie H., Heruc G., Rees A.M., Hadzi-Pavlovic D. Omega-3 fatty acids and mood disorders. Am. J. Psychiatry 2006, 163(6):969-978.
82. Radewicz K., et al. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J. Neuropathol. Exp. Neurol. 2000, 59(2):137-150.
83. Rothermundt M., Arolt V., Weitzsch C., Eckhoff D., Kirchner H. Immunological dysfunction in schizophrenia: a systematic approach. Neuropsychobiology 1998, 37(4):186-193.
84. Roumier A., et al. Prenatal activation of microglia induces delayed impairment of glutamatergic synaptic function. PLoS One 2008, 3(7):e2595.
85. Ruhe H.G., Mason N.S., Schene A.H. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol. Psychiatry 2007, 12(4):331-359.
86. Schwarz M.J., Riedel M., Ackenheil M., Muller N. Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol. Psychiatry 2000, 47(1):29-33.
87. Sijben J.W., Calder P.C. Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease. Proc. Nutr. Soc. 2007, 66(2):237-259.
88. Smith R.S. A comprehensive macrophage-T-lymphocyte theory of schizophrenia. Med. Hypotheses 1992, 39(3):248-257.
89. Smith R.S., Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med. Hypotheses 1995, 45(2):135-141.
90. Song X.Q., Lv L.X., Li W.Q., Hao Y.H., Zhao J.P. The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol. Psychiatry 2009, 65(6):481-488.
91. Sperner-Unterweger B., Whitworth A., Kemmler G., et al. T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients. Schizophr. Res. 1999, 38(1):61-70.
92. Stefansson H., et al. Common variants conferring risk of schizophrenia. Nature 2009, 460(7256):744-747.
93. Steiner J., et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J. Psychiatr. Res. 2008, 42(2):151-157.
94. Stoll A.L., Severus W.E., Freeman M.P., Rueter S., Zboyan H.A., Diamond E., Cress K.K., Marangell L.B. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch. Gen. Psychiatry 1999, 56(5):407-412.
95. Taieb O., Baleyte J.M., Mazet P., Fillet A.M. Borna disease virus and psychiatry. Eur. Psychiatry 2001, 16(1):3-10.
96. Teixeira A.L., Reis H.J., Nicolato R., et al. Increased serum levels of CCL11/eotaxin in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(3):710-714.
97. Theodoropoulou S., Spanakos G., Baxevanis C.N., et al. Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr. Res. 2001, 47(1):13-25.
98. Thomas A.J., et al. Elevation of cell adhesion molecule immunoreactivity in the anterior cingulate cortex in bipolar disorder. Biol. Psychiatry 2004, 55(6):652-655.
99. Tiemeier H., van Tuijl H.R., Hofman A., Kiliaan A.J., Breteler M.M. Plasma fatty acid composition and depression are associated in the elderly: the Rotterdam study. Am. J. Clin. Nutr. 2003, 78(1):40-46.
100. Togo T., et al. Expression of CD40 in the brain of Alzheimer's disease and other neurological diseases. Brain Res. 2000, 885(1):117-121.
101. Torres K.C., Souza B.R., Miranda D.M., et al. The leukocytes expressing DARPP-32 are reduced in patients with schizophrenia and bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33(2):214-219.
102. Torres K.C., Souza B.R., Miranda D.M., et al. Expression of neuronal calcium sensor-1 (NCS-1) is decreased in leukocytes of schizophrenia and bipolar disorder patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33(2):229-234.
103. Torrey E.F., Yolken R.H. At issue: is household crowding a risk factor for schizophrenia and bipolar disorder?. Schizophr. Bull. 1998, 24(3):321-324.
104. Torrey E.F., Miller J., Rawlings R., Yolken R.H. Seasonality of births in schizophrenia and bipolar disorder: a review of the literature. Schizophr. Res. 1997, 28(1):1-38.
105. Torrey E.F., Bartko J.J., Lun Z.R., Yolken R.H. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr. Bull. 2007, 33(3):729-736.
106. Trayhurn P., Bing C., Wood I.S. Adipose tissue and adipokines-energy regulation from the human perspective. J. Nutr. 2006, 136(7 Suppl):1935S-1939S.
107. van Berckel B.N., et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol. Psychiatry 2008, 64(9):820-822.
108. Van den Bergh B.R., Mulder E.J., Mennes M., Glover V. Antenatal maternal anxiety and stress and the neurobehavioural development of the fetus and child: links and possible mechanisms. A review. Neurosci. Biobehav. Rev. 2005, 29(2):237-258.
109. Wang H., et al. Age- and gender-dependent impairments of neurobehaviors in mice whose mothers were exposed to lipopolysaccharide during pregnancy. Toxicol. Lett. 2010, 192(2):245-251.
110. Weigelt K., Carvalho L.A., Drexhage R.C., Wijkhuijs A., Wit H.D., van Beveren N.J., Birkenhäger T.K., Bergink V., Drexhage H.A. TREM-1 and DAP12 expression in monocytes of patients with severe psychiatric disorders. EGR3, ATF3 and PU.1 as important transcription factors. Brain Behav. Immun. 2011, 25:1162-1169.
111. Wierzba-Bobrowicz T., et al. Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol. 2005, 43(2):81-89.
112. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005, 52(2):90-110.
113. Witvrouw M., Schmit J.C., Van Remoortel B., Daelemans D., Este J.A., Vandamme A.M., Desmyter J., De Clercq E. Cell type-dependent effect of sodium valproate on human immunodeficiency virus type 1 replication in vitro. AIDS Res. Hum. Retroviruses 1997, 13(2):187-192.
114. Yolken R.H., Torrey E.F. Viruses, schizophrenia, and bipolar disorder. Clin. Microbiol. Rev. 1995, 8(1):131-145.
115. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Cao L.Y., Shen Y.C. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr. Res. 2002, 57(2-3):247-258.
116. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., Shen Y.C. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J. Clin. Psychiatry 2004, 65(7):940-947.
117. Zhang X.Y., Zhou D.F., Cao L.Y., Wu G.Y., Shen Y.C. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology 2005, 30(8):1532-1538.
118. Zhang X.Y., Zhou D.F., Qi L.Y., et al. Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics. Psychopharmacology (Berl.) 2009, 204(1):177-184.
119. Zorrilla E.P., Cannon T.D., Gur R.E., Kessler J. Leukocytes and organ-nonspecific autoantibodies in schizophrenics and their siblings: markers of vulnerability or disease?. Biol. Psychiatry 1996, 40(9):825-833.
120. Zorrilla E.P., Luborsky L., McKay J.R., et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav. Immun. 2001, 15(3):199-226.